Extended Data Fig. 2: Increase in circulating GP73 elevates fasting blood glucose.
From: GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia
a, Immunoblotting analysis (upper lane) and SDS-PAGE (lower lane) of purified His-tagged rmGP73 (56–401). b Immunoblotting analysis of purified His-tagged rmGP73 (56–401) and GP73 expression in 293 T cells transfected with the indicated plasmids. c, Mouse sandwich ELISA standard curve. d, Plasma GP73 levels in WT and GP73 KO mice (n = 4). P < 0.0001 for GP73 KO versus WT by two-tailed Student’s t-tests. e-f, Plasma GP73 levels in mice after rmGP73 injection at the indicated doses (e) for the indicated times (n = 3 or 4; f). P < 0.0001 for 0.2 mg/kg versus 0 mg/kg, 0.1 mg/kg versus 0 mg/kg and 0.05 mg/kg versus 0 mg/kg by one-way ANOVA followed by Bonferroni’s post hoc test (e). P < 0.0001 for 15 min versus 0 min, P < 0.0001 for 30 min versus 0 min, P = 0.0021 for 60 min versus 0 min by one-way ANOVA followed by Bonferroni’s post hoc test (f). Animal and cell-based studies were performed independently at least three times with comparable results. The data were the means ± SEMs. ***P < 0.01, ***P < 0.001.
